PDCD1 and melanoma: Then, we performed a pooled analysis on four melanoma cohorts treated with ICIs (the Robert cohort treated with anti-PD-1/L1 or anti-CTLA-4 or combination therapy, the Allen and Snyder cohorts treated with anti-CTLA-4 therapy, and the David cohort treated with anti-PD-1 therapy, n = 464) (13–16).